CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reports

We found 6317 result(s)

human insulin (Entuzity KwikPen)

Last Updated: February 24, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: human insulin
Indications: ​To improve glycemic control in adults and children with diabetes mellitus requiring more than 200 units of insulin per day.

  • Brand Name: Entuzity KwikPen
  • Manufacturer: Eli Lilly Canada Inc.
  • Project Number: SR0672-000
  • Project Status: Active
  • Submission Type: Initial

romosozumab (Evenity )

Last Updated: February 24, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: romosozumab
Indications: The treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture.

  • Brand Name: Evenity
  • Manufacturer: Amgen Canada Inc.
  • Project Number: SR0676-000
  • Project Status: Active
  • Submission Type: Initial

budesonide (Jorveza )

Last Updated: December 22, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: budesonide
Indications: Indicated for the induction and maintenance of clinico-pathological remission in adults with eosinophilic esophagitis (EoE).

  • Brand Name: Jorveza
  • Manufacturer: AVIR Pharma Inc
  • Project Number: SR0666-000
  • Project Status: Active
  • Submission Type: Initial

nintedanib (Ofev)

Last Updated: December 22, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: nintedanib
Indications: Treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (also known as progressive fibrosing ILD)

  • Brand Name: Ofev
  • Manufacturer: Boehringer Ingelheim (Canada) Ltd.
  • Project Number: SR0654-000
  • Project Status: Active
  • Submission Type: Initial

osimertinib (Tagrisso )

Last Updated: February 24, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: osimertinib
Indications: Tagrisso (osimertinib) is indicated as adjuvant therapy after tumour resection in patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations. • A validated test is required to identify EGFR mutation-positive status (exon 19 deletions or exon 21 (L858R) substitution mutations) prior to treatment.

  • Brand Name: Tagrisso
  • Manufacturer: AstraZeneca Canada Inc.
  • Project Number: PC0246-000
  • Project Status: Pending
  • Submission Type: Initial

luspatercept (Reblozyl )

Last Updated: February 23, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: luspatercept
Indications: Reblozyl (luspatercept for injection) is indicated for:  the treatment of adult patients with red blood cell (RBC) transfusion-dependent anemia associated with beta(β)-thalassemia.  the treatment of adult patients with transfusion-dependent anemia requiring at least two RBC units over 8 weeks resulting from very low- to intermediate-risk myelodysplastic syndromes (MDS) who have ring sideroblasts and who have failed or are not suitable for erythropoietin-based therapy.

  • Brand Name: Reblozyl
  • Manufacturer: Celgene Inc., a Bristol Myers Squibb company
  • Project Number: SR0670-000
  • Project Status: Received
  • Submission Type: Initial

budesonide/ glycopyrronium /formoterol fumarate (TBC)

Last Updated: February 23, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: budesonide/ glycopyrronium /formoterol fumarate
Indications: budesonide/ glycopyrronium /formoterol fumarate is a combination of an inhaled corticosteroid (ICS), long-acting muscarinic antagonist (LAMA), and a long-acting beta2-adrenergic agonist (LABA), indicated for the long-term maintenance treatment to reduce exacerbations of chronic obstructive pulmonary disease (COPD), and to relieve symptoms in patients with COPD, including chronic bronchitis and/or emphysema.

  • Brand Name: TBC
  • Manufacturer: AstraZeneca Canada Inc.
  • Project Number: SR0675-000
  • Project Status: Active
  • Submission Type: Initial

risperidone (Perseris )

Last Updated: February 23, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: risperidone
Indications: ​Treatment of schizophrenia in adults.

  • Brand Name: Perseris
  • Manufacturer: HLS Therapeutics Inc.
  • Project Number: SR0671-000
  • Project Status: Active
  • Submission Type: Initial

givosiran (Givlaari)

Last Updated: February 23, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: givosiran
Indications: ​Treatment of acute hepatic porphyria (AHP) in adults

  • Brand Name: Givlaari
  • Manufacturer: Alnylam Netherlands B.V.
  • Project Number: SR0679-000
  • Project Status: Received
  • Submission Type: Initial

daunorubicin and cytarabine (Vyxeos)

Last Updated: February 23, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: daunorubicin and cytarabine
Indications: For the treatment of adults with newly diagnosed therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

  • Brand Name: Vyxeos
  • Manufacturer: Jazz Pharmaceuticals Canada Inc.
  • Project Number: PC0237-000
  • Project Status: Active
  • Submission Type: Initial